Savara, Inc. · NASDAQ:SVRA

Savara — Investor Presentation (June 2017)

22 slides from Savara's investor presentation, June 2017

  1. Slide 1: Corporate Presentation

    CORPORATE PRESENTATION JUNE 2017

  2. Slide 2: Safe Harbor Statements

    SAFE HARBOR STATEMENTS Forward Looking Statements. Savara Inc. (“Savara” or the “Company”) cautions you that statements in this presentation that are not a description of historical fact are forward-looking statements which may be identified by the use of words such as “expect,” “intend,” “plan,” “a

  3. Slide 3: Savara Overview (NASDAQ: SVRA)

    SAVARA OVERVIEW (NASDAQ: SVRA) • Clinical Stage Specialty Pharmaceutical Company… …Focused on Rare Respiratory Diseases Unique products for conditions with no approved therapeutics Known treatment concepts Over $1B peak sales potential* Public offering closed June 2017 with $42.9 million in gross pr

  4. Slide 4: Molgradex

    MOLGRADEX Inhaled GM-CSF for Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

  5. Slide 5: PAP: Excess of Surfactant in the Lungs

    PAP: EXCESS OF SURFACTANT IN THE LUNGS US prevalence of ~2500 patients Typical onset 30-50 ys Anti-GM-CSF antibodies cause accumulation of surfactant in the alveoli Decreased oxygen delivery Hypoxia and shortness of breath Currently treated by whole lung lavage (WLL) • Mechanism of disease well unde

  6. Slide 6: Inhaled GM-CSF Promising in Academic Studies

    INHALED GM-CSF PROMISING IN ACADEMIC STUDIES* Improvement in alveolar to arterial aPAP patient oxygen gradient ((A-a)DO2) before inhaled GM-CSF After 6 months of inhaled GM-CSF • Published experience from treatment of more than 80 aPAP patients suggests potential for significant impact on oxygenatio

  7. Slide 7: Molgradex: First Inhaled GM-CSF

    MOLGRADEX: FIRST INHALED GM-CSF Inhalation solution of Direct lung delivery to overcome rhGM-CSF functional GM-CSF deficiency Proprietary cell bank for Orphan status exclusivity GM-CSF manufacturing (7 yrs US + 10 yrs EU) PARI eFlow® Indication extension Nebulizer opportunity 7

  8. Slide 8: Molgradex: Global Pivotal Study Enrolling

    MOLGRADEX: GLOBAL PIVOTAL STUDY ENROLLING Preclinical Phase I Phase III (Complete) (Complete) (Ongoing) Inhalation tox and Healthy Pivotal safety volunteers U.S., EU & Japan pharmacology (n=42) PAP Patients (n=90) Data read expected Q4/2018 Findings Molgradex well consistent with tolerated with a Pr

  9. Slide 9: Phase I – Consistent WBC Response to Each Dose

    PHASE I – CONSISTENT WBC RESPONSE TO EACH DOSE • Safety in healthy volunteers comparable to placebo • Potent dose-dependent pharmacodynamic effect 9

  10. Slide 10: Design of Ongoing Molgradex Phase III Study

    DESIGN OF ONGOING MOLGRADEX PHASE III STUDY Period 1- Double-blind Period 2- Follow-up* n=30, 300µg, daily dosing *Option to prescribe open-label Molgradex, every other week dosing Screening n=30, 300µg, daily dosing every other week n=30, placebo W 48 BL W4 W8 W 12 W 16 W 20 W 24 Primary Endpoint S

  11. Slide 11: AeroVanc

    AEROVANC Inhaled Vancomycin for MRSA in Cystic Fibrosis

  12. Slide 12: High Unmet Need for Inhaled MRSA Treatment

    HIGH UNMET NEED FOR INHALED MRSA TREATMENT CF Prevalence (US) 30,000 patients, 26% MRSA infected Persistent lung infections managed with chronic inhaled antibiotics Source: 2015 CFF Patient Registry MRSA infection associated with worse clinical outcomes No approved inhaled MRSA antibiotic, emerging

  13. Slide 13: AeroVanc: First Inhaled MRSA Antibiotic

    AEROVANC: FIRST INHALED MRSA ANTIBIOTIC Inhaled Dry Powder Orphan 7 yrs + QIDP 5 yrs Vancomycin (total 12 years exclusivity) Drug Directly to Site of Infection Grants from CFF & NIH Designated Fast Track Manufacturing at by the FDA Commercial Scale 13

  14. Slide 14: AeroVanc Phase III Preparations Underway

    AEROVANC PHASE III PREPARATIONS UNDERWAY Preclinical Phase I Phase II Phase III* (Complete) (Complete) (Complete) (Planned) Inhalation tox & Healthy Proof of Concept Pivotal safety volunteers (n=18) PC / DB PC / DB pharmacology CF patients (n=7) CF Patients (n=87) CF Patients (n=200) Primary Enrollm

  15. Slide 15: Phase II: MRSA in Sputum - Primary Endpoint Met

    PHASE II: MRSA IN SPUTUM - PRIMARY ENDPOINT MET ITT population, n = 87 patients, 32mg and 64mg pooled • Proof of concept established • Microbiology not acceptable to FDA as Phase III primary endpoint 15

  16. Slide 16: 32 mg Dose Selected for Phase III Study

    32 MG DOSE SELECTED FOR PHASE III STUDY PK Population, AeroVanc treatments only, n=11 • Vancomycin trough concentrations in high excess over MIC at both doses • ~ 50 % premature study drug discontinuations at 64 mg dose 16

  17. Slide 17: FEV1 Improvement Consistent with TOBI Data

    FEV1 IMPROVEMENT CONSISTENT WITH TOBI DATA PP population, 32 mg dose cohort, < 21 years of age, n = 16, post hoc analysis • Best FEV1 improvement in young patients • Similar FEV1 response profile in prior TOBI studies • Absolute change in FEV1 selected as Phase III primary endpoint • Phase III to be

  18. Slide 18: Improvement in Time to Other Antibiotics

    IMPROVEMENT IN TIME TO OTHER ANTIBIOTICS Time to use of other antibiotics ITT, 32 mg dose cohort, < 21 years of age, n = 20 , post hoc analysis • Prolongation of time to use of other antibiotics • In chronic use, a new treatment cycle would start at day 56, and events (use of other antibiotics) woul

  19. Slide 19: Phase III Design (Per FDA Guidance)

    PHASE III DESIGN (PER FDA GUIDANCE) Period 1- Double-blind Period 2- Open-label AeroVanc 32mg, n = 100 Screening AeroVanc 32mg, n = ~150-170 Placebo, n = 100 W 48 BL W4 W8 W 12 W 16 W 20 W 24 Primary Endpoint Secondary Endpoints • FEV1 improvement at Week 4 • Time to use of another and Week 20 (abso

  20. Slide 20: Anticipated Corporate Milestones

    ANTICIPATED CORPORATE MILESTONES Molgradex Top Line AeroVanc Phase III Results from Phase III Enrollment to Start Study AeroVanc NDA H1 ‘17 H2 ‘17 H1 ‘18 H2 ‘18 2019 2020 Molgradex Indication Aironite Phase II AeroVanc Top Line Molgradex NDA / Expansion Strategy to Top Line Results Results MAA be An

  21. Slide 21: Slide 21

  22. Slide 22: Management & Board of Directors

    MANAGEMENT & BOARD OF DIRECTORS Executive Team Board of Directors Rob Neville, CEO Nevan Elam Serial entrepreneur / Evity exit $100M / Series A CEO Antriabio, Former head of Nektar lead investor Inhalation Rick Hawkins Dr. Taneli Jouhikainen, President & COO CEO Lumos, Founder and former CEO Serial

Savara — Investor Presentation (June 2017) on 6ix